Trial · NCT00024167

Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

NCT00024167, Phase 3, Terminated, M.D. Anderson Cancer Center; results first posted 2016-03-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer. Trials, record NCT00024167. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00024167

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
NCT number: NCT00024167
Status: Terminated
Phases: Phase 3
Enrollment: 265 participants, actual
Lead sponsor: M.D. Anderson Cancer Center
Conditions: Prostate Cancer
Interventions: Docetaxel, Doxorubicin hydrochloride, Estramustine phosphate sodium, Ketoconazole, Prednisone, Vinblastine, Strontium chloride Sr 89, Dexamethasone
First posted: 2003-01-27
Last updated: 2016-03-22
Results first posted: 2016-03-22

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Survival From Randomization	Followed every 4 weeks from randomization until death, up to 7 years.	Overall survival (OS) was computed using the number of months from the date of randomization to the date of death. Participants still alive were censored at the last follow-up date. Kaplan-Meier methodology was used to evaluate OS.
Secondary	Overall Survival From Registration	Followed every 4 weeks from registration until death, up to 7 years.	Overall survival (OS) was computed using the number of months from the date of registration to the date of death. Participants still alive were censored at the last follow-up date. Kaplan-Meier methodology was used to evaluate OS.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Survival From Randomization	Followed every 4 weeks from randomization until death, up to 7 years.		months	MEDIAN
SECONDARY	Overall Survival From Registration	Followed every 4 weeks from registration until death, up to 7 years.		months	MEDIAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Overall Survival From Randomization	Induction Treatment + Strontium-89	24.2	95% Confidence Interval 19.8 to 29.8	months
Overall Survival From Randomization	Induction Treatment + No Strontium-89	22.8	95% Confidence Interval 17.7 to 27.7	months
Overall Survival From Registration	Induction Treatment + Strontium-89	27.9	95% Confidence Interval 23.6 to 34.2	months
Overall Survival From Registration	Induction Treatment + No Strontium-89	26.6	95% Confidence Interval 21.1 to 32.2	months

Source ClinicalTrials.gov

Participant flow10

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Induction Treatment + Strontium-89	65
Overall Study	STARTED	Induction Treatment + No Strontium-89	62
Overall Study	Induction Treatment Option 1 Completed	Induction Treatment + Strontium-89	22
Overall Study	Induction Treatment Option 1 Completed	Induction Treatment + No Strontium-89	21
Overall Study	Induction Treatment Option 2 Completed	Induction Treatment + Strontium-89	43
Overall Study	Induction Treatment Option 2 Completed	Induction Treatment + No Strontium-89	41
Overall Study	COMPLETED	Induction Treatment + Strontium-89	12
Overall Study	COMPLETED	Induction Treatment + No Strontium-89	15
Overall Study	NOT COMPLETED	Induction Treatment + Strontium-89	53
Overall Study	NOT COMPLETED	Induction Treatment + No Strontium-89	47

Source ClinicalTrials.gov

Adverse events378

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Bone Pain	Musculoskeletal and connective tissue disorders	Induction Treatment	4	138	4
other	Bone Pain	Musculoskeletal and connective tissue disorders	Induction Treatment + Strontium-89	2	65	2
other	Bone Pain	Musculoskeletal and connective tissue disorders	Induction Treatment + No Strontium-89	2	62	2
other	Nausea	Gastrointestinal disorders	Induction Treatment	11	138	14
other	Nausea	Gastrointestinal disorders	Induction Treatment + Strontium-89	2	65	2
other	Nausea	Gastrointestinal disorders	Induction Treatment + No Strontium-89	5	62	7
other	Vomiting	Gastrointestinal disorders	Induction Treatment	7	138	9
other	Vomiting	Gastrointestinal disorders	Induction Treatment + Strontium-89	0	65	0
other	Vomiting	Gastrointestinal disorders	Induction Treatment + No Strontium-89	1	62	1
other	Fatigue	General disorders	Induction Treatment	16	138	18

1 to 10 of 378Source ClinicalTrials.gov

See all 378 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Induction Treatment
Total, all-cause mortality	Induction Treatment + Strontium-89
Total, all-cause mortality	Induction Treatment + No Strontium-89
Total, other adverse events	Induction Treatment	34	138
Total, other adverse events	Induction Treatment + Strontium-89	12	65
Total, other adverse events	Induction Treatment + No Strontium-89	13	62
Total, serious adverse events	Induction Treatment	77	138
Total, serious adverse events	Induction Treatment + Strontium-89	53	65
Total, serious adverse events	Induction Treatment + No Strontium-89	47	62

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
16258090	RESULT

Source PubMed

Grants2

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years	Source
P30CA016672	The University of Texas MD Anderson Cancer Center Support Grant (CCSG)	KOONG, ALBERT	UNIVERSITY OF TX MD ANDERSON CAN CTR	NATIONAL CANCER INSTITUTE	1985 to 2026	NIH RePORTER
U10CA045809	The UT MD Anderson Cancer Center Community Clinical Oncology Program Research Bas	WOLFF, ROBERT	UNIVERSITY OF TX MD ANDERSON CAN CTR	NATIONAL CANCER INSTITUTE	1987 to 2013	NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00024167

GET https://conductscience.org/api/trials/v1/NCT00024167/events?page=2

API reference For AI assistants